Polmacoxib
From Wikipedia, the free encyclopedia
![]() |
|
Clinical data | |
---|---|
Trade names | Acelex |
Identifiers | |
|
|
Synonyms | CG100649 |
CAS Number | 301692-76-2 |
PubChem (CID) | 9841854 |
ChemSpider | 8017569 |
UNII | IJ34D6YPAO |
ChEMBL | CHEMBL166863 |
Chemical and physical data | |
Formula | C12H16FNO4S |
Molar mass | 361.3914 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
Polmacoxib (Acelex) is a nonsteroidal anti-inflammatory drug (NSAID) used to treat osteoarthritis. It was developed as CG100649 and approved for use in South Korea in February 2015.[1] It inhibits the enzymes carbonic anhydrase and COX-2. A study in healthy volunteers showed drug effects on urinary prostaglandin metabolites for both CG100649 and celecoxib that suggest a similar cardiovascular risk profile.[2] Further work by this group developed dose-exposure relationsships of CG100649 to guide clinical development strategies. [3]
See also[edit]
References[edit]
- ^ "CrystalGenomics Receives MFDS Approval for Acelex® (Polmacoxib)". PR Newswire.
- ^ Skarke, C.; Alamuddin, N.; Lawson, J. A.; Cen, L.; Propert, K. J.; Fitzgerald, G. A. (2012). "Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649". Clinical Pharmacology & Therapeutics. 91 (6): 986–93. doi:10.1038/clpt.2012.3. PMC 3740579
. PMID 22278334.
- ^ Hirankarn, S.; Barrett, J.S.; Alamuddin, N.; Fitzgerald, G. A.; Skarke, C. (2013). "GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose–Exposure Relationships to Define Clinical Development Strategies". Clinical Pharmacology in Drug Development. 2 (4): 379–386. doi:10.1002/cpdd.47.
![]() |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |